Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

glucarpidase (Voraxaze)

glucarpidase is an FDA-licensed reference biologic from BTG International Inc..

351(a) biologicBLA 125327 BTG International Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2012

Reference product

Originator biologic
351(a)BLA 125327

Voraxaze glucarpidase

BTG International Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for glucarpidase from the RCSB Protein Data Bank (PDB 1CG2).

3D molecular structure of glucarpidase (PDB entry 1CG2)

Interactive biological assembly from PDB entry 1CG2. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference glucarpidase product.

    14 yr 11 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    7 yr 9 mo ago

glucarpidase: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for glucarpidase.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.